FGP
REGN icon

Freestone Grove Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Freestone Grove Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$23.7M Sell
30,625
-10,784
-26% -$8.26M 0.17% 191
2025
Q4 		$32M Sell
41,409
-22,820
-36% -$15.5M 0.23% 144
2025
Q3 		$36.1M Buy
64,229
+20,818
+48% +$11.8M 0.27% 136
2025
Q2 		$22.8M Buy
+43,411
New +$24.2M 0.17% 185

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Freestone Grove Partners's REGN Position: Q1 2026 in Review

Freestone Grove Partners reduced its Regeneron Pharmaceuticals (REGN) stake by 26% in Q1 2026, selling an estimated $8.26M and leaving 30,625 shares worth $23.7M. The position accounts for 0.17% of the portfolio, ranked #191.

Freestone Grove Partners first reported a position in REGN in Q2 2025 and has held it in 4 quarters since. The position peaked at $36.1M in Q3 2025. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Freestone Grove Partners held 30,625 shares of Regeneron Pharmaceuticals worth $23.7M as of Q1 2026.
  • Freestone Grove Partners sold 10,784 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $8.26M.
  • Regeneron Pharmaceuticals made up 0.17% of Freestone Grove Partners's portfolio in Q1 2026, its #191 holding.
  • Freestone Grove Partners first reported a position in Regeneron Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • Freestone Grove Partners's Regeneron Pharmaceuticals position peaked at $36.1M in Q3 2025.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Freestone Grove Partners's 13F filing for Q1 2026, filed 15 May 2026.